94 related articles for article (PubMed ID: 16180961)
1. Atypical antipsychotics and the burden of disease.
Simpson GM
Am J Manag Care; 2005 Sep; 11(8 Suppl):S235-41. PubMed ID: 16180961
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bipolar mania with atypical antipsychotics.
Chengappa KN; Suppes T; Berk M
Expert Rev Neurother; 2004 Nov; 4(6 Suppl 2):S17-25. PubMed ID: 16279862
[TBL] [Abstract][Full Text] [Related]
3. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
4. The implications of weight changes with antipsychotic treatment.
Sussman N
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
[TBL] [Abstract][Full Text] [Related]
5. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder.
Ketter TA; Nasrallah HA; Fagiolini A
Psychopharmacol Bull; 2006; 39(1):120-46. PubMed ID: 17065977
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments for bipolar disorder: safety and adverse effect profiles.
Marken PA; Pies RW
Ann Pharmacother; 2006 Feb; 40(2):276-85. PubMed ID: 16403851
[TBL] [Abstract][Full Text] [Related]
7. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.
Aparasu RR; Jano E; Johnson ML; Chen H
Am J Geriatr Pharmacother; 2008 Oct; 6(4):198-204. PubMed ID: 19028375
[TBL] [Abstract][Full Text] [Related]
9. Atypical antipsychotics: considerations for Medicaid coverage.
Surles RC
Am J Manag Care; 2005 Sep; 11(8 Suppl):S248-53. PubMed ID: 16180963
[TBL] [Abstract][Full Text] [Related]
10. The safety and tolerability of atypical antipsychotics in bipolar disorder.
Seemüller F; Forsthoff A; Dittmann S; Born C; Bernhard B; Severus WE; Grunze H
Expert Opin Drug Saf; 2005 Sep; 4(5):849-68. PubMed ID: 16111448
[TBL] [Abstract][Full Text] [Related]
11. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.
Nasrallah HA
Mol Psychiatry; 2008 Jan; 13(1):27-35. PubMed ID: 17848919
[TBL] [Abstract][Full Text] [Related]
13. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
[TBL] [Abstract][Full Text] [Related]
14. [Atypical antipsychotics in the elderly].
van Melick EJ;
Tijdschr Gerontol Geriatr; 2004 Dec; 35(6):240-5. PubMed ID: 15704604
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
Compton MT; Miller AH
Psychopharmacol Bull; 2002; 36(1):143-64. PubMed ID: 12397853
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic agents in the treatment of bipolar mania.
Tohen M; Vieta E
Bipolar Disord; 2009 Jun; 11 Suppl 2():45-54. PubMed ID: 19538685
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of emerging pharmacological treatments for bipolar disorder.
Dunner DL
Bipolar Disord; 2005 Aug; 7(4):307-25. PubMed ID: 16026484
[TBL] [Abstract][Full Text] [Related]
18. Abnormal glucose metabolism in patients treated with antipsychotics.
Scheen AJ; De Hert MA
Diabetes Metab; 2007 Jun; 33(3):169-75. PubMed ID: 17412628
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
